An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality

Virological, Serological, and Antiviral Studies in an Imported Human Case of Avian Influenza A(H7N9) Virus in Taiwan

(2013) Pi-Han Lin et al.   CLINICAL INFECTIOUS DISEASES

The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome

(2013) T. Baranovich et al.   JOURNAL OF INFECTIOUS DISEASES

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance

(2013) Yunwen Hu et al.   LANCET

The first case of H7N9 influenza in Taiwan

(2013) Sui-Yuan Chang et al.   LANCET

Characterization of H7N9 influenza A viruses isolated from humans

(2013) Tokiko Watanabe et al.   NATURE

Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus

(2013) Rongbao Gao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China

(2013) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection

(2012) R. B. Moss et al.   JOURNAL OF INFECTIOUS DISEASES

Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein

(2009) Gallen B. Triana-Baltzer et al.   PLoS One